BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Provided By GlobeNewswire
Last update: Apr 16, 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients.
Read more at globenewswire.com11.85
-0.47 (-3.81%)
NASDAQ:BCTXW (10/17/2025, 4:30:01 PM)
After market: 0.0507 -0.01 (-12.44%)0.0579
0 (-1.86%)
Find more stocks in the Stock Screener
